NCT01213173

Evaluation of Succinate Metoprolol on Heart Rate in the Stable Angina Patients

A Randomised, Open Label, Parallel Group, Multicentre, Phase IV Study on the Effect of 8 Weeks Succinate Metoprolol (Betaloc ZOK®) (95 - 190 mg) on Heart Rate in the Stable Angina Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 251 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effects of Succinate Metoprolol(Betaloc ZOK®) (95 - 190 mg) on heart rate in the Stable angina patients.

Conditions

• Angina Pectoris

Interventions

Type	Name	Description
DRUG	Succinate Metoprolol (Betaloc ZOK®)	treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
DRUG	Succinate Metoprolol (Betaloc ZOK®)	Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure\<100mmHg and heart rate \<45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-10-01
• Last updated: 2014-09-05
• Results posted: 2013-08-26

Locations

10 sites across 1 country: China